This activity is expired and is no longer available for CME credit.


Best of RA Forum 2014

Author(s)/Faculty: Leonard H. Calabrese, DO; Jeffrey Curtis, MD, MS, MPH; M. Elaine Husni, MD, MPH; Jonathan Kay, MD
Release Date: 12/15/2014Expiration Date: 12/14/2015
Credit Type: CMENumber of Credits: 0
Content Type: MultimediaProvider:
In the United States, the prevalence of rheumatoid arthritis (RA) has been reported to range from 0.5% to 1.0% of the general population, and incidence rate increases with age. Up to 45% of people with RA experience activity limitation, 31% experiencing work limitation, and disability increases with disease duration. With the knowledge that RA is initiated by immune mechanisms, therapy has evolved from an eminently symptomatic treatment to an immunosuppressive approach. Over the past 15 years, immunomodulating therapies have been shown to slow the progression of joint damage and improve the clinical manifestations of RA. Ten agents, in 6 therapeutic classes, are currently approved for clinical use. Ongoing studies examining the role of the newer cytokines in the disease process will improve the understanding of RA pathophysiology and the development of more novel therapies to address unmet medical needs. To date, the strongest surrogate indicators of outcomes for patients with RA are the stage at which the disease presents and is accurately diagnosed, followed by the initiation of appropriate and aggressive treatment. Therefore, clinicians must be knowledgeable about the current RA management guidelines, as well as the tools for disease assessment. Treatment selection and disease management to achieve optimal outcomes demand that physicians are knowledgeable about the role of the immune system in the pathophysiology of RA. In this activity, leading experts will provide a comprehensive discussion of the current understanding of RA pathophysiology, the associated CV risks, disease activity assessment and measures, as well as updated guidelines and RA management strategies based on comparative effectiveness data.